Drugs / ICP-248
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06656494 | Dec 2024 → Jun 2027 expected | acute myeloid leukemia, myelodysplastic syndrome | Beijing InnoCare Pharma Tech Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06351527 | Apr 2024 → Jun 2027 expected | neoplasm of mature B-cells | InnoCare Pharma Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05728658 | Mar 2023 → Aug 2025 overdue | hematopoietic and lymphoid cell neoplasm | Beijing InnoCare Pharma Tech Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07082686 | Aug 2025 → Dec 2027 expected | mantle cell lymphoma | Beijing InnoCare Pharma Tech Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06378138 | May 2024 → Nov 2030 expected | hematopoietic and lymphoid cell neoplasm | Beijing InnoCare Pharma Tech Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ICP-248 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06378138 ↗ |
| Route | Oral | “ICP-248 orally” NCT05728658 ↗ |